OWC Pharmaceutical Research Corp.

43 articles about OWC Pharmaceutical Research Corp.

• If you purchased OWC Pharmaceutical Research Corp. stock between November 2016 and September 2017, you may be eligible for distribution from the Jeffrey Friedland Fair Fund

  2/4/2022

  If you purchased OWC Pharmaceutical Research Corp. stock between November 2016 and September 2017, you may be eligible for distribution from the Jeffrey Friedland Fair Fund

• OWC Pharmaceutical Research Corp. Announces A New Distribution Agreement With Can It Industries, Florida US

  9/14/2020

  Can It Industries, FL, will provide OWC with its distribution channels from North America through South America while seeking for a medical-grade cannabis-infused manufacturing facility with international exporting licenses

• OWC Pharmaceutical Research Corp. Letter to Shareholders for Upcoming Proxy Voting

  8/19/2020

  Shareholders meeting is set for Aug 31st, 2020. The proxy includes proposals for a reverse stock split and authorizing additional shares of capital stock.

• OWC Pharmaceutical Research Corp. Announces Special Meeting of Stockholders

  7/29/2020

  Meeting tentatively scheduled for August 25, 2020 The USPTO recently awarded the company a patent for its Cannabis-based Extracts and Topicals for Skin Disorder. OWC engaged Stanley Wunderlich, CEO, Consulting for Strategic Growth1, Ltd. for IR/PR representation

• OWC Israel's Patent for Cannabis Based Extracts and Topical Formulations for Use in Skin Disorders, Is Allowed for Issuance as a Patent in the USA

  12/16/2019

  OWC Pharmaceutical Research Corp., represented by its wholly-owned subsidiary, One World Cannabis Ltd. announced that, on December 9, 2019, the United States Patent and Trademark Office issued a Notice of Allowance indicating that OWC Israel's Patent Application No. 15/629,230 directed to cannabis based extracts and topical formulations for use in skin disorders, is allowed for issuance as a patent.

• OWC Pharmaceutical Research Corp. to Report Top Line Results (TLR) for a Safety Study on Its Cannabis-based Tablets

  10/7/2019

  OWC Pharmaceutical Research Corp. (OTCQB: OWCP), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, announced today that, on September 25, 2019, One World Cannabis Ltd., a company organized and existing under the laws of Israel and a wholly-owned subsidiary of OWC received Top Line Results

• OWC Pharmaceutical Research Corp, Letter to Shareholders - February 11, 2019

  2/11/2019

  OWC Pharmaceutical Research Corp., a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, issued a letter to shareholders.

• OWC Pharmaceutical Research Corp. Reports Positive Safety Data From Phase 1 (Safety) Clinical Trial for Medical Grade Cannabis Ointment for Treatment of Skin Diseases

  1/30/2019

  The Company is on track to initiate a Phase 2 trial of MSG ointment for the treatment of psoriasis during the third quarter 2019.

• OWC Pharmaceutical Research Corp. to Report Progress on Ointment Care for Skin Diseases

  12/31/2018

  OWC Pharmaceutical Research Corp. reported today that it has been granted a patent in the Czech Republic covering its topical formulations for skin disorders.

• OWC Pharmaceutical Research Corp. to Attend Biotech Showcase 2019

  12/27/2018

  OWC announced today that management will attend Biotech Showcase 2019 to be held in San Francisco, CA on January 7-9, 2019.

• OWC Pharmaceutical Research Corp. Reports the Successful Production of Its Cannabinoid-Enriched Sublingual Disintegrating Tablet

  12/18/2018

  OWC Pharmaceutical Research Corp., reports the successful production of its cannabinoid-enriched sublingual disintegrating tablet, specifically developed as smoking substitute.    

• OWC Pharmaceutical Research Corp Reports Progress in Clinical Trials for Ointment Care for Skin Diseases

  11/29/2018

  The last healthy volunteer in its first ever safety study of cannabis-based topical ointment, was recently admitted in trial which is being conducted at Sheba Medical Center, Tel Hashomer, Israel.

• OWC Pharmaceutical Research Corp. to Report Progress in Clinical Trials for Ointment Care for Skin Diseases

  11/29/2018

  The subject of study is expected to be treated with the ointment during six weeks.

• OWC Pharmaceutical Research Corp Successfully Tests Unique, Innovative Delivery Formulation Aimed at Multiple Myeloma Therapy

  10/22/2018

  OWC Pharmaceutical Research Corp was administered in vivo in an animal model for the first time and was found to be safe and tolerable.

• OWC Pharmaceutical Research Corp Announced Personnel Changes

  8/21/2018

  OWC Pharmaceutical Research Corp. announced that as part of the our preparation for Phase II efficacy study (the "Psoriasis Study") of our cannabinoid-based ointment for the treatment of skin diseases

• OWC Pharmaceutical Research Corp Initiated Final Stage of Cannabinoid-based Topical Ointment Safety Study

  8/1/2018

  OWC Pharmaceutical Research Corp. announced today the initiation of the final stage of its Phase I, placebo controlled, maximal dose study

• OWC Pharmaceutical Research Corp Letter to Shareholders

  7/24/2018

  OWC Pharmaceutical Research Corp. issued a letter to shareholders.

• OWC Pharmaceutical Research Corp. Completes First Part of Cannabis-Based Ointment Safety Study

  6/29/2018

  OWC Pharmaceutical Research Corp. announced a successful completion of the first part of its Phase I, placebo controlled, maximal dose study

• OWC Pharmaceutical Research Corp Completes Development of Next Generation Orally-Disintegrating Tablet

  6/13/2018

  OWC Pharmaceutical Research Corp. announced it has completed the pre-clinical development of its next generation, orally-disintegrating tablet containing cannabis extract with specific amounts of the cannabinoids tetrahydrocannabinol ("THC") and cannabidiol ("CBD").

• OWC Pharmaceutical Research Corp Raises $5 Million in Preferred Stock Sale to Institutional Investor

  5/3/2018

  OWC Pharmaceutical Research Corp. (OWCP), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced the closing of the sale of $5 million of convertible preferred stock to an institutional investor